Search

everythinglearnresearchcommunity

for

Search:↓

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Stopping minoxidil and finasteride for three months caused significant hair loss. The user resumed treatment with 2.5mg oral minoxidil and 0.6mg finasteride and plans to update on progress in three months.

The user stopped finasteride for three months to try for a baby but continued using minoxidil and micro-needling. They are concerned about hair shedding and plan to resume finasteride after the baby is born.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses a user's six-month progress in treating hereditary hair loss using a regimen that includes minoxidil, finasteride, dutasteride, and other medications. Opinions vary on the effectiveness and logic of the treatment, with some users suggesting additional methods like microneedling.

A user shared their one-year progress on dutasteride, noting fuller hair but persistent thinning at the crown. They sought advice on whether to resume minoxidil and in which form, while others inquired about their choice of dutasteride and its effects.

The user experienced continuous hair shedding for 16 months while on finasteride, with periods of improvement. They also used T Gel shampoo and noticed a reduction in hair loss symptoms after 18 months, including the return of their sex drive and normal hair texture.

The user shared progress pictures after 5 months of using finasteride and microneedling, noting they stopped minoxidil recently to test finasteride alone. Another user observed good improvement and advised not to stop using minoxidil.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

An 18-year-old has been using oral finasteride for 4.5 months to address hair thinning noticed since Fall 2022. They report the back of their head feels thicker, but are unsure if it's due to actual progress or placebo effect.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Using 0.25mg of finasteride daily for 7 months resulted in thicker hair and slowed hair recession without side effects. The user plans to continue this dosage and may add dermarolling or ketoconazole shampoo for maintenance.

A user's six month progress with Pyrilutamide, a hair loss treatment; they experienced positive results such as stopped itching and shedding, as well as regrowth, without any side effects.

The conversation discusses concerns about getting a buzz cut years after a FUE hair transplant due to an unnatural look and thinning hair. Suggestions include trying a buzz cut and considering scalp micropigmentation (SMP) as an option.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.

Long-term finasteride users often experience periodic hair shedding due to natural hair cycles, even after several years of use. Some consider switching to dutasteride, but concerns about side effects and the effectiveness of finasteride remain common.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.